UBS Group
NBIX icon

UBS Group’s Neurocrine Biosciences NBIX Stock Holding History

UBS Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-72,000
Closed -$7.02M – 10716
2022
Q2 		$7.02M Hold
72,000
– – ﹤0.01% 2087
2022
Q1 		$6.75M Sell
72,000
-14,800
-17% -$1.25M ﹤0.01% 2262
2021
Q4 		$7.39M Buy
86,800
+82,800
+2,070% +$7.62M ﹤0.01% 2420
2021
Q3 		$384K Buy
+4,000
New +$378K ﹤0.01% 4895
2015
Q1 		– Sell
-53,300
Closed -$1.19M – 9150
2014
Q4 		$1.19M Buy
+53,300
New +$1.01M ﹤0.01% 3426

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group's NBIX Position: Q2 2026 in Review

UBS Group reduced its Neurocrine Biosciences (NBIX) stake by 55% in Q2 2026, selling an estimated $100M and leaving 545,937 shares worth $92M. The position accounts for 0.01% of the portfolio, ranked #1184.

UBS Group first reported a position in NBIX in Q4 2014 and has held it in 47 quarters since. The position peaked at $161M in Q1 2026. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • UBS Group held 545,937 shares of Neurocrine Biosciences worth $92M as of Q2 2026.
  • UBS Group sold 675,099 Neurocrine Biosciences shares in Q2 2026, an estimated $100M.
  • Neurocrine Biosciences made up 0.01% of UBS Group's portfolio in Q2 2026, its #1184 holding.
  • UBS Group first reported a position in Neurocrine Biosciences in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Neurocrine Biosciences position peaked at $161M in Q1 2026.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.